RBC Europe’s Filana Therapeutics FLNA Stock Holding History

RBC Europe’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-280	Closed	-$23.9K	–	1265
2021 Q2	$23.9K	Hold	280	–	–	﹤0.01%	771
2021 Q1	$12.6K	Buy	+280	New	+$11K	﹤0.01%	872

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

RBC Europe's FLNA Position: Q3 2021 in Review

RBC Europe sold out of Filana Therapeutics (FLNA) in Q3 2021, closing a stake of 280 shares — an estimated $23.9K sold.

RBC Europe first reported a position in FLNA in Q1 2021 and held it in 2 quarters. The position peaked at $23.9K in Q2 2021. 180 funds tracked by Wall St. Rank hold FLNA as of Q3 2021.

RBC Europe reported no remaining Filana Therapeutics position as of Q3 2021 after selling out during the quarter.
RBC Europe sold 280 Filana Therapeutics shares in Q3 2021, an estimated $23.9K.
RBC Europe first reported a position in Filana Therapeutics in Q1 2021 and held it in 2 quarters.
RBC Europe's Filana Therapeutics position peaked at $23.9K in Q2 2021.
180 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2021.

Based on RBC Europe's 13F filing for Q3 2021, filed 9 Nov 2023.